↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

Overview of attention for article published in Therapeutics and Clinical Risk Management, August 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
2 tweeters
facebook
2 Facebook pages
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
72 Mendeley
Title
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
Published in
Therapeutics and Clinical Risk Management, August 2015
DOI 10.2147/tcrm.s55313
Pubmed ID
Authors

William Bobo, Marc Kelliny, Paul Croarkin, Katherine Moore

Abstract

This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 72 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 17%
Other 10 14%
Student > Doctoral Student 9 13%
Student > Ph. D. Student 9 13%
Student > Bachelor 6 8%
Other 12 17%
Unknown 14 19%
Readers by discipline Count As %
Medicine and Dentistry 17 24%
Psychology 10 14%
Neuroscience 8 11%
Agricultural and Biological Sciences 5 7%
Chemistry 4 6%
Other 8 11%
Unknown 20 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2021.
All research outputs
#5,034,958
of 18,738,748 outputs
Outputs from Therapeutics and Clinical Risk Management
#230
of 1,143 outputs
Outputs of similar age
#64,098
of 243,998 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#15
of 57 outputs
Altmetric has tracked 18,738,748 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,143 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,998 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.